Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Melissa BersanelliDiana GiannarelliUgo De GiorgiSandro PignataMassimo Di MaioElena VerzoniAlberto ClementeValentina GuadalupiDiego SignorelliMarcello TiseoRaffaele GiustiMarco FilettiMarilena Di NapoliLorenzo CalvettiAlessandro CappettaPaola ErmacoraDiego ZaraFausto BarbieriCinzia BaldessariVieri ScottiFrancesca MazzoniAntonello VecciaPamela Francesca GuglielminiMarco MaruzzoErnesto RossiFrancesco GrossiChiara CasadeiAlessio CortelliniFrancesco VerderameVincenzo MontesarchioMimma RizzoManlio MencoboniFable ZustovichLucia FratinoSaverio CinieriGiorgia NegriniMaria BanziMariella SorarùPaolo Andrea ZucaliGaetano LacidognaAntonio RussoNicola BattelliGiuseppe FornariniClaudia MucciariniSergio BracardaAndrea BonettiDebora PezzuoloLucia LongoDonata SartoriMauro IannopolloLuigi CavannaFausto MeriggiDavide TassinariClaudia CorboAngela GernoneVeronica PratiSimona CarnioPasqualina GiordanoAngela Maria DicoratoClaudio VerusioFrancesco AtzoriFrancesco CarrozzaStefania GoriAntonino CastroSara PilottoVanja VaccaroElisabetta GarzoliFrancesco Di CostanzoEvaristo MaielloRoberto LabiancaCarmine PintoMichele TognettoSebastiano ButiPublished in: Therapeutic advances in medical oncology (2020)
COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.
Keyphrases
- advanced cancer
- coronavirus disease
- sars cov
- palliative care
- respiratory syndrome coronavirus
- study protocol
- risk factors
- clinical trial
- papillary thyroid
- cross sectional
- case report
- cardiovascular events
- squamous cell
- randomized controlled trial
- type diabetes
- cardiovascular disease
- coronary artery disease
- young adults
- childhood cancer